Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pediatrix Medical GroupFRA:PDC +1.80%54 Debt-to-EBITDA is 2.96 as of Mar. 2026, which is 35% below its 10-year median of 4.55. GuruFocus rates FRA:PDC with a GF Score™ of 54/100 and a GF Value™ of €11.41. The stock has 8 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Pediatrix Medical Group ranks better than 50.63% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Pediatrix Medical Group's Debt-to-EBITDA or its related term are showing as below:
FRA:PDC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.34 Med: 4.55 Max: 23.48
Current: 2.21
During the past 13 years, the highest Debt-to-EBITDA Ratio of Pediatrix Medical Group was 23.48. The lowest was -23.34. And the median was 4.55.
FRA:PDC's Debt-to-EBITDA is ranked better than 50.63% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs FRA:PDC: 2.21
Pediatrix Medical Group (FRA:PDC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pediatrix Medical Group Debt-to-EBITDA Related Terms
Pediatrix Medical Group Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PDC vs SEM, AGL, SGRY: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Pediatrix Medical Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pediatrix Medical Group Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pediatrix Medical Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Pediatrix Medical Group (FRA:PDC) has a Debt-to-EBITDA of 2.96 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pediatrix Medical Group. This is 35% below median its historical median of 4.55. According to the industry distribution chart, Pediatrix Medical Group ranks #236 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 49.4%.
Is Pediatrix Medical Group's Debt-to-EBITDA too high?
Pediatrix Medical Group's current Debt-to-EBITDA of 2.96 is 35% below median its 10-year median of 4.55. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. Pediatrix Medical Group's value of 2.96 is 31.6% above this industry median. Based on the distribution chart, Pediatrix Medical Group ranks #236 out of 478 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pediatrix Medical Group has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's Debt-to-EBITDA compare to SEM and AGL?
According to the Healthcare Providers & Services industry distribution chart, Pediatrix Medical Group ranks #236 out of 478 companies for Debt-to-EBITDA. This puts Pediatrix Medical Group in the upper half of its industry. The industry median Debt-to-EBITDA is 2.25. Pediatrix Medical Group's value of 2.96 is 31.6% above this benchmark. While the company's 10-year median is 4.55 vs. the industry median of 2.25, Pediatrix Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pediatrix Medical Group's current Debt-to-EBITDA of 2.96 is 31.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pediatrix Medical Group. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pediatrix Medical Group's current Debt-to-EBITDA is 2.96, which is 35% below median its own 10-year median of 4.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Pediatrix Medical Group (FRA:PDC) has a current Debt-to-EBITDA of 2.96. The stock's GF Value™ is €11.41, compared to a current price of €22.60 — trading 98.1% above its estimated fair value. The current Debt-to-EBITDA is 2.96, which is 35% below median its 10-year median of 4.55 and 31.6% above the Healthcare Providers & Services industry median of 2.25. Pediatrix Medical Group's overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current Debt-to-EBITDA is 2.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?
Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued.
The current stock price of €22.60 is trading 98.1% above its estimated GF Value™ of €11.41.
Key valuation signals for FRA:PDC:
Debt-to-EBITDA: 2.96 (35% below median its 10-year median of 4.55)
GF Value™: €11.41 vs. price of €22.60 (98.1% above fair value)
Industry Position: 31.6% above the Healthcare Providers & Services median (#236 of 478)
No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
54GF Score
Get the complete analysis for FRA:PDC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDC has been successfully added to your 
